| Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates |
Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 |
globenewswire.com |
2025-05-08 10:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates |
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, to be developed for the treatment of acne SAN MATEO, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2024, and provided recent corporate updates. |
globenewswire.com |
2025-03-12 09:30:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne |
TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the clearance of its Investigational New Drug (IND) application for TVB-3567, the Company's second fatty acid synthase (FASN) inhibitor. |
globenewswire.com |
2025-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences' Denifanstat Should Be Worth More Today |
Denifanstat is SGMT's leading FASN inhibitor for MASH. It has shown strong Phase 2b results and earned the FDA Breakthrough Therapy designation. SGMT also has a diversified pipeline on acne, solid tumors, and GBM, enhancing its optionality beyond its primary MASH focus. They've recently shown some positive trial milestones, including the first Phase 3 dosing. |
seekingalpha.com |
2025-03-07 18:27:05 |
Czytaj oryginał (ang.) |
| Sagimet: More Than Just A MASH Drug Development Biotech |
Sagimet Biosciences Inc.'s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024. The global acne treatment market size is projected to grow from $17.48 billion by 2032. Results from phase 3 study by partner Ascletis, using denifanstat for treatment of patients with Acne Vulgaris, expected by Q2 of 2025. |
seekingalpha.com |
2024-11-14 17:56:32 |
Czytaj oryginał (ang.) |
| Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne |
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) o nce-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024. |
prnewswire.com |
2024-11-12 08:30:00 |
Czytaj oryginał (ang.) |
| Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat |
Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's unique FASN inhibition mechanism effectively reduces liver fibrosis, positioning it as a superior treatment for advanced MASH compared to competitors like Tirzepatide. SGMT's robust financials, including $188.5 million in liquidity and no debt, provide a solid foundation for advancing Denifanstat through Phase 3 trials. |
seekingalpha.com |
2024-10-18 19:10:17 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology |
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis - - Results support advancement of denifanstat into Phase 3 development - |
globenewswire.com |
2024-10-11 11:00:00 |
Czytaj oryginał (ang.) |
| SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug |
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data. |
zacks.com |
2024-10-02 20:01:11 |
Czytaj oryginał (ang.) |
| Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH |
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024 SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to denifanstat for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). |
globenewswire.com |
2024-10-01 11:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference at 2:30 PM ET on Monday, October 7, 2024. |
globenewswire.com |
2024-10-01 04:05:00 |
Czytaj oryginał (ang.) |
| Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit |
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that an oral presentation highlighting denifanstat's anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the 8th Annual MASH Drug Development Summit being held in Boston on September 24-26, 2024. |
globenewswire.com |
2024-09-12 11:30:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks with 190% Growth Potential According to Wall Street Analysts |
Penny stocks are a fascinating category of investment opportunities. |
247wallst.com |
2024-08-12 19:27:22 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors |
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. |
globenewswire.com |
2024-08-01 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide |
Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive results reinforcing its potential, especially for hepatic-impaired patients. Eli Lilly's Tirzepatide presents strong competition for Denifanstat in MASH treatment, showing higher efficacy in recent trials. |
seekingalpha.com |
2024-07-31 16:24:33 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat |
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET |
globenewswire.com |
2024-06-10 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 |
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH |
globenewswire.com |
2024-06-06 09:00:00 |
Czytaj oryginał (ang.) |
| Leerink Partnrs Weighs in on Sagimet Biosciences Inc.’s Q2 2024 Earnings (NASDAQ:SGMT) |
Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Analysts at Leerink Partnrs increased their Q2 2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a research note issued to investors on Wednesday, May 15th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.35) per share for the quarter, up from their previous forecast of ($0.41). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.89) per share. Leerink Partnrs also issued estimates for Sagimet Biosciences’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.77) EPS, FY2024 earnings at ($1.91) EPS, FY2025 earnings at ($3.64) EPS, FY2026 earnings at ($5.18) EPS, FY2027 earnings at ($7.22) EPS and FY2028 earnings at ($5.65) EPS. SGMT has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Sagimet Biosciences in a report on Thursday. SVB Leerink assumed coverage on Sagimet Biosciences in a report on Monday, March 25th. They set an “outperform” rating and a $26.00 price objective on the stock. JMP Securities decreased their price target on Sagimet Biosciences from $47.00 to $46.00 and set a “market outperform” rating on the stock in a report on Wednesday, February 7th. Finally, The Goldman Sachs Group decreased their price target on Sagimet Biosciences from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $38.80. Check Out Our Latest Research Report on SGMT Sagimet Biosciences Stock Performance SGMT stock opened at $4.62 on Monday. Sagimet Biosciences has a 1-year low of $2.13 and a 1-year high of $20.71. The business has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $5.64. Institutional Investors Weigh In On Sagimet Biosciences A number of institutional investors have recently added to or reduced their stakes in SGMT. Teacher Retirement System of Texas bought a new stake in Sagimet Biosciences during the third quarter valued at about $220,000. Platinum Investment Management Ltd. purchased a new stake in Sagimet Biosciences in the third quarter valued at about $3,378,000. Victory Capital Management Inc. purchased a new stake in Sagimet Biosciences in the third quarter valued at about $158,000. New York State Common Retirement Fund purchased a new stake in Sagimet Biosciences in the third quarter valued at about $56,000. Finally, FMR LLC purchased a new stake in Sagimet Biosciences in the third quarter valued at about $23,517,000. Institutional investors own 87.86% of the company’s stock. Insider Transactions at Sagimet Biosciences In related news, CEO David Happel acquired 12,100 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The shares were bought at an average price of $5.27 per share, with a total value of $63,767.00. Following the completion of the transaction, the chief executive officer now directly owns 639,200 shares in the company, valued at $3,368,584. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.60% of the company’s stock. About Sagimet Biosciences (Get Free Report) Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. |
https://www.defenseworld.net |
2024-05-20 05:06:36 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Inc. to Post Q2 2024 Earnings of ($0.40) Per Share, HC Wainwright Forecasts (NASDAQ:SGMT) |
Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Analysts at HC Wainwright raised their Q2 2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a report released on Thursday, May 16th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($0.40) for the quarter, up from their previous forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.89) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.93) EPS, FY2024 earnings at ($2.15) EPS, FY2025 earnings at ($5.09) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($5.47) EPS and FY2028 earnings at ($3.03) EPS. Other analysts have also recently issued research reports about the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Sagimet Biosciences in a report on Monday, March 25th. SVB Leerink began coverage on Sagimet Biosciences in a report on Monday, March 25th. They issued an “outperform” rating and a $26.00 price target on the stock. JMP Securities lowered their price target on Sagimet Biosciences from $47.00 to $46.00 and set a “market outperform” rating on the stock in a report on Wednesday, February 7th. Finally, The Goldman Sachs Group decreased their price objective on Sagimet Biosciences from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $38.80. Check Out Our Latest Analysis on SGMT Sagimet Biosciences Stock Down 2.7 % NASDAQ:SGMT opened at $4.62 on Monday. The business’s 50-day moving average price is $4.64 and its two-hundred day moving average price is $5.64. Sagimet Biosciences has a twelve month low of $2.13 and a twelve month high of $20.71. Insider Activity at Sagimet Biosciences In other news, CEO David Happel acquired 12,100 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were bought at an average cost of $5.27 per share, with a total value of $63,767.00. Following the acquisition, the chief executive officer now owns 639,200 shares in the company, valued at approximately $3,368,584. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 17.60% of the stock is currently owned by insiders. Hedge Funds Weigh In On Sagimet Biosciences A number of large investors have recently bought and sold shares of the stock. FMR LLC purchased a new position in Sagimet Biosciences in the 3rd quarter worth approximately $23,517,000. Vanguard Group Inc. increased its stake in Sagimet Biosciences by 364.9% in the 1st quarter. Vanguard Group Inc. now owns 1,139,407 shares of the company’s stock worth $6,176,000 after purchasing an additional 894,319 shares during the period. Rock Springs Capital Management LP purchased a new position in Sagimet Biosciences in the 3rd quarter worth approximately $6,498,000. Ikarian Capital LLC purchased a new position in Sagimet Biosciences in the 1st quarter worth approximately $2,236,000. Finally, RTW Investments LP bought a new stake in shares of Sagimet Biosciences in the 3rd quarter worth approximately $3,522,000. 87.86% of the stock is owned by hedge funds and other institutional investors. About Sagimet Biosciences (Get Free Report) Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. See Also Five stocks we like better than Sagimet Biosciences What is the Dogs of the Dow Strategy? Overview and Examples MarketBeat Week in Review – 5/13 – 5/17 What is Put Option Volume? Take-Two Interactive Software Offers 2nd Chance for Investors What Are Dividend Champions? How to Invest in the Champions Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:06:33 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 |
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet's topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet's topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH |
globenewswire.com |
2024-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates |
Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 |
globenewswire.com |
2024-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 |
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL) International Liver Congress 2024 held in Milan, Italy from June 5-8, 2024. |
globenewswire.com |
2024-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer |
SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. |
globenewswire.com |
2024-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 |
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 |
globenewswire.com |
2024-04-22 12:00:00 |
Czytaj oryginał (ang.) |